The goalpost for a health care system solely focused on personalized medicine always gets closer when the FDA clears devices and technologies like Medtronic's (NYS:MDT) GenCut biopsy system. The tool works with the company's superDimension navigation system – a device that's often called a GPS tracking system for the lung. Medtronic reported launching the device, earlier this week. Read More
